TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PENNSAID

DICLOFENAC SODIUM
Approved 2009-11-04
2
Indications
--
Phase 3 Trials
16
Years on Market

Details

Status
Discontinued
First Approved
2009-11-04
Routes
TOPICAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: DICLOFENAC SODIUM

PENNSAID Approval History

Loading approval history...

What PENNSAID Treats

2 FDA approvals

Originally approved for its first indication in 2009 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PENNSAID FDA Label Details

Pro

PENNSAID Patents & Exclusivity

Latest Patent: Aug 2030

Patents (25 active)

US8546450 Expires Aug 9, 2030
US8217078 Expires Jul 10, 2029
US8618164 Expires Jul 10, 2029
US8741956 Expires Jul 10, 2029
US9370501 Expires Jul 10, 2029
US9375412 Expires Jul 10, 2029
US9415029 Expires Jul 10, 2029
US8252838 Expires Apr 21, 2028
US9132110 Expires Oct 17, 2027
US9168305 Expires Oct 17, 2027
+ 15 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.